Reuters logo
7 months ago
BRIEF-Prometic reacquires plasminogen rights from Hematech
January 5, 2017 / 12:03 PM / 7 months ago

BRIEF-Prometic reacquires plasminogen rights from Hematech

1 Min Read

Jan 5 (Reuters) - Prometic Life Sciences Inc :

* Prometic reacquires plasminogen rights from Hematech

* Prometic Life Sciences Inc - regains 100 pct ownership of profits from future sales of plasminogen for congenital deficiency

* Prometic Life Sciences Inc - hematech continues to hold taiwanese rights to ppps as cmo supplier to prometic

* Prometic Life Sciences Inc - consideration for acquiring rights included issuance of 1.7 million shares of prometic to Hematech

* Prometic Life Sciences Inc - amended its licensing agreement originally entered into with Hematech Biotherapeutics Inc in May 2012

* Prometic Life Sciences Inc - consideration included payment of mid-single digit royalty as well as other non-cash considerations to license agreement Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below